Navigation Links
BioConvergence® Presents Case Study on Temperature Controlled Pharmaceutical Products
Date:10/19/2013

Bloomington, Indiana (PRWEB) October 18, 2013

BioConvergence team members Désirée Valentine and Travis Hudson presented their newest case study (including outcomes of yielding a 99.7 percent excursion-free shipping rate) at the 11th Annual Cold Chain & Temperature Management Global Forum in Chicago, IL earlier this month.

The conference, led by IQPC, focused on shipping regulations, strategies, and trends within the life sciences industry, with special emphasis on maintaining product integrity through temperature management.

“There is plenty of evidence that suggests that a product’s temperature (and the associated fluctuations) can have profound impacts on a product’s stability, and therefore, its therapeutic effectiveness,” relates Valentine, Senior Supply Chain Manager at BioConvergence. “Because of this, BioConvergence is committed to keeping our clients’ products within appropriate temperature conditions while at our facility and throughout transit. This year, our team has implemented key changes that have resulted in improved metrics and additional value to clients. In presenting this data at IQPC, we hope that others will utilize this case study to realize similar results and promote improvements throughout the pharmaceutical supply chain.”

These improvements, as were discussed in Valentine and Hudson’s presentation, are as follows:

  •     Yielded a 99.7 percent excursion-free rate
  •     Decreased Average Days in Transit by over 1 day per shipment
  •     Reduced Days in Transit (50% reduction in “Delivery Past Qualification” time)
  •     Improved coordination, both internally and externally
  •     Established processes for continual improvement moving forward

When asked how BioConvergence achieved these results, Hudson, Associate Process Engineer at BioConvergence, responded, “We began by having a clear picture of the results we wanted to see: improvements to key performance indicators and partnerships, as well as reductions to excursion rates. Next, we began an in-depth analysis of our existing processes and flagged five specific root causes that were interfering with outcomes. After strategically addressing each of these items, we began to see improvements in our metrics. This process has become the standard at BioC in promoting continual improvements.”

In addition to presenting this case study, Valentine and Hudson also led a roundtable discussion during the conference entitled, “How to Create Value through Designing and Implementing a Shipping Lane Qualification for High Value Pharmaceutical Products.”

To learn more about the framework BioConvergence developed, download the full case study at http://www.bioc.us/iqpc.

About BioConvergence

BioConvergence is a contract service provider to the life sciences industry, offering outsourcing partnerships for formulation development, testing, production, and supply chain services. Headquartered in Bloomington, Indiana, BioC has over 50 employees with more than four centuries’ worth of combined experience in the pharmaceutical industry. BioC’s unique E-Transparency® System provides transparency and flexibility to its clients, while offering superior, quality-driven outsourcing services. For more information, visit http://www.bioc.us.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11245946.htm.


'/>"/>
Source: PRWeb
Copyright2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioConvergence®, Contract Manufacturing Organization for the Life Sciences Industry, Announces New Board of Directors
2. CEO of BioConvergence® Receives Women Excel Bloomington Award for Outstanding Leadership and Service
3. BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment
4. BioConvergence® Launches New Blog Aimed at Exploring Best Practices of Pharmaceutical and Biotechnology Industries
5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
6. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
7. FarHawk Marketing Services Represents IonBench™ and MS Noise™ at the Greater Boston Mass Spectrometry Discussion Group Corporate Night October 3rd
8. San Francisco Business Times Presents: Richmond! Your Home Front for Business
9. Quorum Review’s Mitchell Parrish Presents at Embracing Change: Clinical Research in the 21st Century
10. Bayer CropScience Presents on Bee Health and Stewardship at International Pollinator Conference
11. Clinovo Presents Its Paper ‘Cloud for Clinical Trials’ at Society for Clinical Data Management (SCDM) Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
(Date:2/15/2017)... ... 2017 , ... Park Systems , a leader in Atomic Force Microscopy ... drastically boosts productivity with single click reliable nanoscale images, is now available on Park ... and taking the image once done manually by the operator producing high quality nanoscale ...
(Date:2/15/2017)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced ... and full year ended December 31, 2016. ... as we continued to demonstrate strong growth in ... Fanapt," said Mihael H. Polymeropoulos, M.D., Vanda,s President ... important 2017 milestones underscores Vanda,s commitment to bringing ...
(Date:2/15/2017)... ... February 15, 2017 , ... ... hold its sixth annual open house and technology show, Morris Madness, March 14-15, ... metal cutting demos from Okuma, Tsugami and Hardinge Group in addition to displays ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
Breaking Biology News(10 mins):